Multicenter retrospective study identifies determinants of nivolumab response in head and neck squamous cell carcinoma, highlighting potential predictive biomarkers for immunotherapy.
In view of improving biomarkers predicting the efficacy of immunotherapy for head and neck squamous cell carcinoma (R/M HNSCC), this multicenter retrospective study aimed to identify clinical, tumor microenvironmental, and genomic factors that are related to therapeutic response to the anti- Programmed cell death protein 1 (PD-1) antibody, nivolumab, in patients with R/M HNSCC.
No takes yet. Share an insight, caveat, or question.
Tsujikawa et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: